Healthcare Industry News: Spinal Cord Stimulator
News Release - April 4, 2012
Anulex Technologies, Inc. Announces FDA Clearance for Expanded Indications of fiXate(TM) Tissue BandNew technology aids consistent securement of Spinal Cord Stimulator leads and intrathecal pain catheters in less than 30 seconds
MINNETONKA, Minn.--(Healthcare Sales & Marketing Network)--Anulex Technologies, Inc., a privately held medical device manufacturer, announced today that the U.S. Food and Drug Administration (FDA) has cleared additional indications for use of its fiXate™ Tissue Band product. The fiXate Tissue Band previously received clearance for securing Spinal Cord Stimulation (SCS) lead anchors to fascia or interspinous/supraspinous ligaments in patients with chronic, intractable pain of the trunk and/or limbs. The new indication allows for securing intrathecal pain pump catheters in the same tissue.
The Anulex Technologies fiXate™ Tissue Band provides more consistent SCS lead and intrathecal catheter anchor securement by offering a novel delivery system that facilitates efficient fixation to surrounding tissue in less than 30 seconds. By utilizing an in-line design, fiXate facilitates a smaller incision to allow less invasive surgery.
After trying fiXate™ Tissue Bands for securing intrathecal catheter and spinal cord stimulation leads, Dr. Michael Gofeld from the Center for Pain Relief at University of Washington Medical Center had this to say: “fiXate firmly secures the catheter anchor in the desired place. Additionally, implantation time and incision size is minimized in patients of all sizes.” Jeff Peters, Anulex’s Chief Executive Officer, goes on to say, “with the expansion of indications for fiXate Tissue Band, Anulex continues to demonstrate its commitment to developing novel and clinically relevant solutions for soft tissue fixation and repair.”
About Anulex Technologies, Inc.
Anulex Technologies, Inc. is dedicated to the development and commercialization of unique and proprietary soft tissue repair and fixation products. This latest clearance builds on our existing product platform which includes the XcloseTM Plus Tissue Repair System and the VersacloseTM Tissue Repair System which utilize proprietary InvisilocTM Technology enabling surgeons to easily re-approximate soft tissue to facilitate the healing process. More information on the Company can be found at www.anulex.com.
fiXate, Xclose, Versaclose and Anulex are trademarks of Anulex Technologies, Inc.
Source: Anulex Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.